MITRE on Tuesday announced two new collaborations based around its mCODE data standard. One will bring voice recognition capabilities to the oncology dataset, and another will see it working with the Mayo Clinic to build out and automate that and other data platforms to enable better care for cardiology, COVID-19 and more Continue reading →

August 29, 2020 09:30 ET | Source: MyoKardia, Inc. EXPLORER-HCM Data Presented During Live Hot Line Session at ESC Congress 2020 with Simultaneous Publication in The Lancet Presentation Expands on Positive Topline Results Showing Early, Sustained Reductions in Biomarkers of Cardiac Wall Stress and Myocardial Injury Mavacamten Demonstrated Broad Treatment Effect, with Consistent Benefit Across Primary and Secondary Endpoints Among All Prespecified Patient Subgroups MyoKardia to Host a Virtual Analyst and Investor Event to Review Data on Monday, August 31 at 8:00 a.m. EDT BRISBANE, Calif., Aug Continue reading →

In recent years, the advancement of wearable technology and health/performance-related heart monitoring systems have provided clinicians an opportunity to bridge the gap between consumers and proactive care for atrial fibrillation risk. Namely, a common yet under-diagnosed condition like atrial fibrillation (AF)linked to greater major adverse cardiovascular events (MACE) and even dementiacould be better addressed with the bevy of data coming available from consumer technology. In a virtual presentation at the European Society of Cardiology (ESC) 2020 Congress this weekend, Emma Svennberg, MD, PhD, of the Karolinska University Hospital in Sweden, discussed the progress made in this venture and how it pertains to a greater questionand the name of her session: Will digital health finally solve the problem of asymptomatic atrial fibrillation screening Continue reading →

As the bestselling drug in the heart failure space, Novartis' Entresto suffered a stinging setback last year in a novel indicationbut there were some signs of hope. Now, a new Entresto study is again showing promise in that patient population, but it's not a resounding win. Continue reading →

The Centers for Medicare & Medicaid Services (CMS) has partnered with the American College of Cardiology (ACC) to include several National Cardiovascular Data Registry (NCDR) measures as part of their Alternate Quality Measures Set. Not only can NCDR measures now do double duty, but for sites that opt in to using these alternative measures, the ACC itself will be submitting the data directly to CMS, reducing reporting burden on NCDR sites. "There was feedback from the clinician community that the measures weren't clinically specific," said Christine Perez, JD, the director of Payer & Care Delivery Policy at the ACC. Continue reading →

August 29, 2020 09:00 ET | Source: Medtronic plc ESC Congress: New Research Highlights First-Line Use of Cryoablation as Highly Effective, and with Improved Quality of Life Scores DUBLIN, Aug. 29, 2020 (GLOBE NEWSWIRE) -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced clinical trial results demonstrating superiority of the Arctic Front Advance Cardiac Cryoballoon and Freezor MAX Cardiac CryoAblation Catheter for the first-line treatment (prior to drug therapy) of recurrent symptomatic paroxysmal atrial fibrillation (PAF) compared to antiarrhythmic drug (AAD) treatment Continue reading →

Both therapeutic and prophylactic anticoagulation in patients hospitalized with COVID-19 significantly reduce the risk of in-hospital mortality, as well as the need for intubation, when compared with no systemic anticoagulation, according to an observational analysis of patients treated at five New York City hospitals. Overall, the rates of major bleeding were low, although the risk was slightly higher in patients treated with therapeutic anticoagulation. Its an observational study, said lead investigator Girish Nadkarni, MD (Icahn School of Medicine at Mount Sinai, New York, NY), discussing the clinical significance of the mortality signal, but it has led to insights that have led to our ongoing clinical trial Continue reading →

While the primary endpoint was not met, exploratory analysis suggests a signal of reduced risk of disease progression of initial triple oral combination therapy vs initial double oral therapy for Pulmonary Arterial Hypertension (PAH) patients Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson, today announced results from the Phase 3b TRITON trial, the first randomised controlled study evaluating the efficacy and safety of initial triple oral combination therapy (UPTRAVI [selexipag], OPSUMIT [macitentan] and tadalafil) compared to initial double oral combination therapy (placebo, macitentan and tadalafil) in newly diagnosed, treatment-nave patients with pulmonary arterial hypertension (PAH). Study results were featured as an oral presentation as part of the digital European Society of Cardiology Congress held 29 August 1 September 2020. Continue reading →

Fewer than one in five patients enrolled in the COAPT trial of the MitraClip (Abbott) were super-responders to their assigned therapies, with more seen in the percutaneous intervention group than in the medical control group. But understanding at the outset which patients will benefit most from the clip remains murky. Writing in an early-online publication of the Journal of the American College of Cardiology, Paul A. Continue reading →

(UPDATED) Investigators who led a widely publicized cardiac magnetic resonance (CMR) study showing that COVID-19 may cause lingering cardiac damage have responded to questions raised on social media challenging their findings. Eike Nagel, MD, and Valentina Puntmann, MD, PhD (both University Hospital Frankfurt, Germany), issued a correction this week in JAMA Cardiology, stating they reviewed and reanalyzed their data after TCTMD alerted to them Twitter discussions about their work Continue reading →